Clinuvel Pharmaceuticals (CLVLY) Stock Price, News & Analysis

Company Overview

Clinuvel Pharmaceuticals Limited is an Australian biopharmaceutical company headquartered in Melbourne, specializing in the development and commercialisation of photoprotective and phototherapeutic solutions. The company’s research centers on harnessing the skin’s natural photoprotective pathways by modulating the melanocortin system, with a view to addressing a range of skin disorders and conditions that are exacerbated by ultraviolet light exposure.

The company’s flagship product, Scenesse (afamelanotide), is the first systemic photoprotective drug approved by both the European Medicines Agency and the U.S. Food and Drug Administration for the prevention of phototoxic reactions in patients with erythropoietic protoporphyria (EPP). Beyond EPP, Clinuvel maintains an active clinical pipeline exploring additional indications such as vitiligo, acute UV-induced DNA damage and other disorders of pigment regulation. Its proprietary formulations and delivery methods are designed to offer consistent, controlled dosing and improved patient outcomes.

Clinuvel serves markets across Europe, North America and the Middle East, operating a manufacturing facility in Europe alongside regulatory and commercial offices abroad. The company’s commercial infrastructure supports ongoing growth in specialty dermatology clinics and hospitals, while the research and development arm continues to expand the therapeutic applications of its photomedicine technology. Clinuvel is guided by a management team with extensive experience in drug development, regulatory affairs and global product rollout.

Key Stats

• Today's Range: $7.80 to $8.00
• 50-Day Range: $6.42 to $8.72
• 52-Week Range: $6.00 to $10.18
• Volume: 1,762 shs
• Average Volume: 3,249 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CLVLY Stock Analysis - Frequently Asked Questions

How have CLVLY shares performed this year?

Clinuvel Pharmaceuticals' stock was trading at $7.70 at the start of the year. Since then, CLVLY shares have increased by 1.4% and is now trading at $7.8061.

How do I buy shares of Clinuvel Pharmaceuticals?

Shares of CLVLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Ex-Dividend for 9/29 Dividend: 9/08/2025
• Record date for 9/29 Dividend: 9/09/2025
• Today: 9/18/2025
• Dividend Payable: 9/29/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:CLVLY
• CIK: 1290877
• Web: www.clinuvel.com
• Phone: (139) 660-4900
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A